Noncompliance to Apixaban for A-Fib Due to Many Factors
Improved communication with patients about cost, bleeding, and monitoring may increase compliance
Atrial Fibrillation
Individual A-Fib Episodes Tied to Recent Alcohol Intake
AF episodes also linked to higher odds of peak blood alcohol concentration, total area under curve of alcohol exposure
Non-Vitamin K Antagonist Oral Anticoagulants vs Warfarin in NVAF Patients
Findings may help with decision-making in this high-risk patient population.
Amplatzer Amulet Approved to Reduce Thromboembolic Risk in Atrial Fibrillation
The Amulet device is designed for complete immediate closure of the left atrial appendage using dual-seal technology.
Racial/Ethnic Disparities Seen in Anticoagulant Initiation for A-Fib
Disparities seen among VA patients both for initiating any anticoagulant therapy and for initiating direct-acting oral anticoagulant use
Rates of Adverse Events Lower With Apixaban for A-Fib in Older Adults
Apixaban the only direct oral anticoagulant linked to lower adverse event rates than warfarin for patients with atrial fibrillation across frailty levels
Omega-3 Fatty Acids Tied to Better Cardiovascular Outcomes
Cardiovascular risk reduction more prominent with EPA monotherapy versus EPA + DHA therapy
New-Onset SVT Following Colonoscopy Bowel Prep Explored in Case Series
A significant percentage of affected patients were observed to have dilated atria and left ventricular hypertrophy.
Cardiac Monitor Implant Detects A-Fib in More Stroke Patients
Rate of incident AF over 12 months higher with implant versus usual care with external cardiac monitoring in patients with ischemic stroke
Kidney Impairment Influences Safety, Efficacy of Anticoagulants for AFib
Investigators found an incremental increase in risks from oral anticoagulants as kidney function decreased, highlighting the need for more research to better understand bleeding risk and net benefit of treatment in the CKD population.
